Venkatesh V Chari, PhD
Staff Scientist, Assay Development, Research & Development Team, DiscoverX Corporation, Fremont, CA, USA
Dr. Chari earned his Ph.D in Cancer Biology at the University of Toledo – Medical Center, Toledo, OH, in 2013. At the University of Toledo, he worked on drug development projects in the fields of breast cancer and prostate cancer. He published multiple original articles in internationally acclaimed journals like Journal of Biological Chemistry and the European Journal of Medicinal Chemistry, as well as numerous abstracts, which were presented at international conferences.
Dr. Chari has several years of industrial experience. After graduating from the University of Toledo, he joined Thermo Fisher Scientific as a Staff Scientist where he contributed to several projects including cell-based assay development, capillary electrophoresis, digital PCR and OpenArray qPCR platforms.
Currently, Dr. Chari works at DiscoverX Corporation where his research work includes developing cell-based assays for screening small molecules, bio-similars, antibodies and other compounds using proprietary DiscoverX platforms such as PathHunter™ (β-Arrestin2 recruitment assay), HitHunter™ (cAMP Assay for small molecules), KILR™ (antibody-dependent cell mediated cytotoxicity assay) and others. At DiscoverX, he is involved in Custom Assay Design projects as well as new product development. Dr. Chari serves as a referee for multiple peer-reviewed journals including American Journal of Cancer Research, Experimental Biology & Medicine, Current Cancer Therapy Reviews, and others. He is an active member of the American Association for Cancer Research and the Endocrine Society.